Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
MGZ Medical Genetics Center | RCV002290084 | SCV002581756 | uncertain significance | Tyrosinase-positive oculocutaneous albinism | 2022-08-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003101670 | SCV003442804 | pathogenic | not provided | 2022-10-03 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the OCA2 protein in which other variant(s) (p.Tyr827*) have been determined to be pathogenic (PMID: 29345414). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This frameshift has been observed in individual(s) with ocular albinism (PMID: 27734839). This variant is not present in population databases (gnomAD no frequency). This sequence change results in a frameshift in the OCA2 gene (p.Tyr802Leufs*48). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 37 amino acid(s) of the OCA2 protein and extend the protein by 10 additional amino acid residues. |